Digital pathology is an emerging field of medical science that uses digital technologies to capture, store, analyze, and share data associated with medical images. It is revolutionizing the way pathologists diagnose and treat diseases.

In digital pathology, tissue samples are scanned and converted into digital images. These images are then analyzed by computer algorithms that can detect patterns and features associated with diseases. This can help pathologists make more accurate diagnoses, as well as identify new treatments and drug targets.

Currently, Digital Pathology Market is projected to reach USD 1,371 million by 2026 from USD 736 million in 2021, at a CAGR of 13.2% during the forecast period. The growth in the digital pathology market is mainly driven by factors such as the increasing adoption of digital pathology to enhance lab efficiency, rising incidence of cancer, and growing applications of digital pathology in drug development and companion diagnostics.

The market is segmented by type into enzymatic debridement, mechanical debridement, autolytic debridement, and others. The enzymatic debridement segment is expected to hold the largest market share over the forecast period, as it is the most widely used method for Digital Pathology Market. Additionally, the rising demand for enzymatic debridement products and services is expected to drive the market growth.

The market is further segmented by end-use into hospitals, clinics, and homecare settings. Hospitals are expected to hold the largest share of the market, as they offer specialized services for Digital Pathology Market. The increasing number of hospitals and clinics offering specialized wound care services is expected to fuel the market growth.

Request for assumptions & how numbers were triangulated.

The scanners segment accounted for the largest share of the Digital Pathology market.

Based on products, the digital pathology market has been segmented into scanners, software, and storage systems. The large share of the scanners segment can be attributed to the high price of scanners and the increasing adoption of digital pathology solutions.

The human pathology segment accounted for the largest share of the Digital Pathology market

Based on type, the global digital pathology market is segmented into human pathology and veterinary pathology. The human pathology segment accounted for the largest share of the digital pathology market. This is due to the increasing number of cancer research activities and growing collaborations among research institutes, universities, and pathology laboratories.

The drug discovery, segment accounted for the largest share of the Digital Pathology market.

Based on application, the digital pathology market is segmented into drug discovery, disease diagnosis, and training & education. The drug discovery segment accounted for the largest share of the digital pathology market. Growth in R&D expenditure fuelled by the need for numerous preclinical and clinical studies performed during the drug discovery and development process is a major factor responsible for market growth.

Digital pathology also provides a platform for collaboration among pathologists and other healthcare professionals. Digital images can be shared between different healthcare institutions, allowing for more efficient diagnosis and treatment. It also provides a platform for research and development of new treatments and drugs.

Digital pathology is also being used to develop personalized medicine. By analyzing digital images of tissue samples, doctors can identify the unique characteristics of an individual's disease. This can help them tailor treatments to better suit the individual's needs.

Digital pathology is an exciting field that is changing the way we diagnose and treat diseases. It is revolutionizing the way healthcare professionals collaborate and providing new opportunities for personalized medicine. As technology continues to advance, digital pathology will become an even more integral part of medical science.

Download an Illustrative Overview:

Recent Developments

  • In September 2021, Visiopharm (Denmark) and Agilent Technologies, Inc. (US) collaborated to co-market Visiopharm’s portfolio of CE-IVD marked AI-driven Precision Pathology software and Agilent’s automated pathology staining solutions portfolio.
  • In August 2021, Sectra AB (Sweden) and University Medical Center Utrecht (Netherlands) signed an agreement under which UMC uses Sectra’s pathology module for effective multidisciplinary discussions among pathologists and radiologists.
  • In May 2021, Sectra AB (Sweden) and Institut Curie (France) signed an agreement which allows the digitization of pathology at Institut Curie. The pathologists in Institut Curie can access cases, digital tools, and AI applications through the Sectra pathology solution.
  • In April 2021, Leica Biosystems (US) and Paige.AI, Inc. (US) partnered for Paige’s AI-enabled research software for tumor detection, grading, and quantification to Leica Biosystems digital pathology platform in countries throughout North America and Europe.

Content Source: